Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06723236 · ClinicalTrials.gov registry record · Phase 1
A Study of MGC028 in Participants With Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumors and Cholangiocarcinoma, sponsored by MacroGenics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 124
- Enrollment target
- 6
- Study locations
NCT06723236: Recruiting Phase 1 study of Advanced Solid Tumors and Cholangiocarcinoma, sponsored by MacroGenics.
NCT06723236 is a Phase 1 study of Advanced Solid Tumors and Cholangiocarcinoma that is actively recruiting participants, run by MacroGenics. The registered enrollment target is 124 participants, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (37% lower). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06723236, a Phase 1 study of Advanced Solid Tumors and Cholangiocarcinoma, is actively recruiting participants, sponsored by MacroGenics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 124 participants
- Enrollment target
- 6
- Study locations
Study Summary
The goal of this clinical trial is to characterize the safety, tolerability, dose-limiting toxicities (DLT), and maximum tolerated dose (MTD) or maximum administered dose of MGC028 (if no MTD is defined). The study will enroll adult participants with relapsed or refractory, unresectable, locally advanced of metastatic solid tumors known to express ADAM9. The main question the study aims to answer is: * What types of side effects will participants experience when receiving MGC028? * Can MGC028 cause cancer to shrink, remain stable, or able to control disease progression of participants with advanced solid tumors? Participants will * Undergo screening procedures to determine eligibility * Receive study treatments initially every 3 weeks. * Have blood samples taken for routine and research tests * Have other examinations to check heart and lung function, and general health status * Be asked about any side effects that may be happening or other medications you are taking. The study doctor will provide treatment for side effects, if necessary. * Have the study doctor assess your tumor status at regular intervals to determine how you are responding to treatment.
Primary Outcome
Types of AEs include Serious Adverse Events (SAEs), and AEs Leading to Treatment Delay or Discontinuation or Dose Reduction, dose limiting toxicities, and AEs of Special Interest. Observation of side effects determines the highest safe dose for further study
Conditions Studied
Interventions
- BIOLOGICAL MGC028
Study Locations (6)
California
- UCSF - Helen Diller Family Cancer Center - San Francisco
Massachusetts
- Dana Farber/Harvard Cancer Center - Boston
Michigan
- South Texas Accelerated Research Therapeutics (START) Midwest - Grand Rapids
New York
- Icahn School of Medicine at Mt. Sinai - New York
Texas
- South Texas Accelerated Research Therapeutics (START) San Antonio - San Antonio
Utah
- South Texas Accelerated Research Therapeutics (START) Mountain Region - West Valley City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2025-02-13 |
| Est. Completion | 2027-04 |
| Phase | Phase 1 |
What NCT06723236 shows while recruiting
NCT06723236 is an interventional study that assigns participants to a tested intervention. The registered 124 participants enrollment target is mid-sized for trials with a published cap, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (37% lower).
The record links to 5 conditions, with Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which MGC028 is the first listed.
NCT06723236 lists 6 locations in 6 states (California, Massachusetts, Michigan).
Frequently Asked Questions
What is clinical trial NCT06723236 about?
NCT06723236 is a clinical study titled "A Study of MGC028 in Participants With Advanced Solid Tumors". The goal of this clinical trial is to characterize the safety, tolerability, dose-limiting toxicities (DLT), and maximum tolerated dose (MTD) or maximum administered dose of MGC028 (if no MTD is defined). The study will enroll adult participants with relapsed or refractory, unresectable, locally adv...
What is the current status of trial NCT06723236?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 124 participants. The study started on 2025-02-13. Estimated completion is 2027-04.
What conditions does trial NCT06723236 study?
This clinical trial studies the following conditions: Advanced Solid Tumors, Cholangiocarcinoma, Colorectal Carcinoma, Pancreatic Carcinoma, NSCLC Adenocarcinoma.
What interventions are being tested in trial NCT06723236?
The interventions under investigation include: MGC028 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06723236?
This trial is sponsored by MacroGenics, which has 36 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06723236 being conducted?
This trial has 6 study locations across California, Massachusetts, Michigan, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06723236's enrollment target sits among peer trials
124 69th of 144 higher than 76 of 144 other Advanced Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
RECRUITING · Phase 1
-
SNV4818 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523014 · 124 participants · Phase 2
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
- NCT02670707 · 124 participants · Phase 3
Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)
- NCT02830724 · 124 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
- NCT04748809 · 124 participants · NA
Effect of Anti-inflammatory Diet in Rheumatoid Arthritis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI